S&P 500   4,998.76 (-0.25%)
DOW   37,959.42 (+0.49%)
QQQ   419.58 (-0.90%)
AAPL   165.44 (-0.96%)
MSFT   400.77 (-0.87%)
META   487.66 (-2.82%)
GOOGL   154.77 (-0.79%)
AMZN   176.19 (-1.69%)
TSLA   149.89 (-0.03%)
NVDA   819.22 (-3.25%)
AMD   151.03 (-2.61%)
NIO   3.88 (-3.00%)
BABA   68.75 (-0.19%)
T   16.38 (+0.31%)
F   12.13 (+0.58%)
MU   109.50 (-2.17%)
GE   151.20 (-1.14%)
CGC   7.76 (-0.89%)
DIS   112.11 (-0.28%)
AMC   3.22 (+10.27%)
PFE   25.59 (+0.79%)
PYPL   62.18 (+0.13%)
XOM   120.71 (+1.85%)
S&P 500   4,998.76 (-0.25%)
DOW   37,959.42 (+0.49%)
QQQ   419.58 (-0.90%)
AAPL   165.44 (-0.96%)
MSFT   400.77 (-0.87%)
META   487.66 (-2.82%)
GOOGL   154.77 (-0.79%)
AMZN   176.19 (-1.69%)
TSLA   149.89 (-0.03%)
NVDA   819.22 (-3.25%)
AMD   151.03 (-2.61%)
NIO   3.88 (-3.00%)
BABA   68.75 (-0.19%)
T   16.38 (+0.31%)
F   12.13 (+0.58%)
MU   109.50 (-2.17%)
GE   151.20 (-1.14%)
CGC   7.76 (-0.89%)
DIS   112.11 (-0.28%)
AMC   3.22 (+10.27%)
PFE   25.59 (+0.79%)
PYPL   62.18 (+0.13%)
XOM   120.71 (+1.85%)
S&P 500   4,998.76 (-0.25%)
DOW   37,959.42 (+0.49%)
QQQ   419.58 (-0.90%)
AAPL   165.44 (-0.96%)
MSFT   400.77 (-0.87%)
META   487.66 (-2.82%)
GOOGL   154.77 (-0.79%)
AMZN   176.19 (-1.69%)
TSLA   149.89 (-0.03%)
NVDA   819.22 (-3.25%)
AMD   151.03 (-2.61%)
NIO   3.88 (-3.00%)
BABA   68.75 (-0.19%)
T   16.38 (+0.31%)
F   12.13 (+0.58%)
MU   109.50 (-2.17%)
GE   151.20 (-1.14%)
CGC   7.76 (-0.89%)
DIS   112.11 (-0.28%)
AMC   3.22 (+10.27%)
PFE   25.59 (+0.79%)
PYPL   62.18 (+0.13%)
XOM   120.71 (+1.85%)
S&P 500   4,998.76 (-0.25%)
DOW   37,959.42 (+0.49%)
QQQ   419.58 (-0.90%)
AAPL   165.44 (-0.96%)
MSFT   400.77 (-0.87%)
META   487.66 (-2.82%)
GOOGL   154.77 (-0.79%)
AMZN   176.19 (-1.69%)
TSLA   149.89 (-0.03%)
NVDA   819.22 (-3.25%)
AMD   151.03 (-2.61%)
NIO   3.88 (-3.00%)
BABA   68.75 (-0.19%)
T   16.38 (+0.31%)
F   12.13 (+0.58%)
MU   109.50 (-2.17%)
GE   151.20 (-1.14%)
CGC   7.76 (-0.89%)
DIS   112.11 (-0.28%)
AMC   3.22 (+10.27%)
PFE   25.59 (+0.79%)
PYPL   62.18 (+0.13%)
XOM   120.71 (+1.85%)
Free Trial
ASX:OCC

Orthocell (OCC) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free OCC Stock Alerts
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
669,530 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
OCC stock logo

About Orthocell Stock (ASX:OCC)

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.

OCC Stock News Headlines

March 26, 2024 | proactiveinvestors.com
Orthocell moves closer to US market clearance and sales
February 29, 2024 | morningstar.com
Orthocell Ltd OCC
April 19, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
February 22, 2024 | proactiveinvestors.com
Orthocell raising $3.5 million; adds heavy hitters to register
January 15, 2024 | finance.yahoo.com
Orthocell (ASX:OCC) shareholders have earned a 23% CAGR over the last five years
January 14, 2024 | au.investing.com
Orthocell appoints former Deputy Prime Minister Kim Beazley as a director
November 13, 2023 | proactiveinvestors.com
Orthocell tendon cell therapy as effective as surgery for chronic tennis elbow
November 1, 2023 | finance.yahoo.com
Orthocell on the cusp of significant growth
April 19, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
October 29, 2023 | proactiveinvestors.com.au
Orthocell and University of Western Australia cement long-term partnership through equity exchange
October 29, 2023 | proactiveinvestors.com
Orthocell and University of Western Australia cement long-term...
October 25, 2023 | finance.yahoo.com
Orthocell Limited's (ASX:OCC) CEO Will Probably Find It Hard To See A Huge Raise This Year
August 23, 2023 | proactiveinvestors.com.au
Orthocell has Striate+™ re-certified under stricter European medical device regulations
August 6, 2023 | au.investing.com
Biotechs play the long game as always in a healthy June quarter
May 28, 2023 | proactiveinvestors.com.au
Orthocell thrilled to welcome John Van Der Wielen as chairman
May 28, 2023 | proactiveinvestors.com
Orthocell appoints experienced executive John Van Der Wielen as independent non-executive chairman
May 25, 2023 | finance.yahoo.com
OCC.AX - Orthocell Limited
April 17, 2023 | proactiveinvestors.com.au
Orthocell kicks off comparator study for nerve repair device Remplir
March 30, 2023 | finance.yahoo.com
Orthocell welcomes globally recognised nerve surgeons to advisory board
March 28, 2023 | proactiveinvestors.com
Orthocell appoints specialist US-based nerve surgeons to medical advisory board
March 7, 2023 | proactiveinvestors.com.au
Orthocell welcomes high profile US-based healthcare specialist to the board
March 7, 2023 | proactiveinvestors.com.au
Orthocell appoints US healthcare specialist as independent non-executive director
March 3, 2023 | finance.yahoo.com
Orthocell First Half 2023 Earnings: AU$0.021 loss per share (vs AU$0.024 loss in 1H 2022)
February 26, 2023 | finanznachrichten.de
The Options Clearing Corporation: OCC Welcomes Jefferies Executive Joseph Lewis to Board of Directors
February 8, 2023 | finance.yahoo.com
Orthocell (ASX:OCC) shareholders have earned a 4.7% CAGR over the last five years
November 1, 2022 | proactiveinvestors.com.au
Orthocell’s Remplir™ added to Australian Prostheses list
November 1, 2022 | msn.com
ASX Biotech Stocks: Surgeons can now be reimbursed for using Orthocell’s nerve repair device
See More Headlines
Receive OCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orthocell and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:OCC
CUSIP
N/A
CIK
N/A
Web
www.orthocell.com.au
Phone
61 8 9360 2888
Fax
N/A
Employees
317
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
A($0.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-7,420,000.00
Net Margins
-154.57%
Pretax Margin
N/A
Return on Equity
-177.01%
Return on Assets
-26.69%

Debt

Debt-to-Equity Ratio
34.88
Current Ratio
4.60
Quick Ratio
5.07

Sales & Book Value

Annual Sales
$4.80 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
3.41
Book Value
A$0.01 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
209,330,000
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
0.09
Beginners Guide To Retirement Stocks Cover
Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Paul Frederick Anderson (Age 58)
    CEO, MD & Executive Director
    Comp: $650.97k
  • Ms. Nicole Jane Telford
    Chief Financial Officer
  • Mr. Alex McHenry
    Chief Operating Officer
  • Prof. Ming Hao Zheng
    Chief Scientific Officer and Member of Medical & Scientific Advisory Board
  • Mr. Tony Macintyre
    Chief Manufacturing Officer
  • Mr. Peter Gordon Webse B.Bus (Age 61)
    FCIS, FCPA, FGIA, M.A.I.C.D., Company Secretary

Key Competitors

View All Competitors

Insiders


OCC Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Orthocell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orthocell investors own include Plug Power (PLUG), Viralytics (VRACY), Genetic Technologies (GTG) and GP Strategies (GPX).

This page (ASX:OCC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research